Orthocell has been named as a biotech stock to watch on a recent episode the Equity Mates Investing Podcast.
The West Australian | Orthocell confirms record $17 million raising to launch in the US
Orthocell’s record $17 million capital raise has been featured in The West Australian newspaper in an article titled “Orthocell confirms record $17 million raising to launch in the US” by journalist Sean Smith.Â
$17 million placement to fund US launch of Remplirâ„¢ and drive further growth
Orthocell has today announced that it has received firm commitments for a $17 million capital raising via an institutional placement.
Meet The Board | Chairman, John Van Der Wielen
The third episode of Orthocell’s ‘Meet the Board’ video series is now online – featuring Chairman, John Van Der Wielen.
Executive Series | Meet The Board | Professor Fiona Wood AM
In the second instalment of the ‘Meet The Board’ video series, we meet Professor Fiona Wood, a world-renowned plastic and reconstructive surgeon, and valued member of the Orthocell Board.
Orthocell Receives Regulatory Approval for Remplirâ„¢ in SingaporeÂ
Orthocell has received regulatory approval from the Health Sciences Authority (HSA) in Singapore, allowing the Company to commence sales of its market leading nerve repair product, Remplirâ„¢
Orthocell Reports Second Consecutive Quarter of Record Revenue
Orthocell has today announced continued growth in sales of its market-leading medical devices, Striate+â„¢ and Remplirâ„¢.
VIDEO | Meet The Board | CEO & MD, Paul Anderson
The first episode of Orthocell’s ‘Meet the Board’ video series is now live – featuring CEO & MD, Paul Anderson.
Launching October 2024 | Meet The Board
As part of a special ‘Meet the Board’ video series launching in October 2024, we are pleased to bring you face to face with the team at the top. Tune in for inspiring insights into their vision for our Company.
Ausbiz | Interview with John Van Der Wielen
Orthocell Chairman, John Van Der Wielen spoke with ausbiz host Nadine Blayney about the Company’s expansion into Canada with dental bone regeneration product, Striate+, and Orthocell’s strong outlook for revenue growth.